#Netherlands #Amsterdam #CGM #diabetes #SIBIONICS

SIBIONICS GS3: Redefining Glucose Monitoring

During the recent ATTD 2025 conference in Amsterdam, SIBIONICS made a significant mark by unveiling its latest innovation, the GS3, touted as the world's thinnest Continuous Glucose Monitor (CGM). This cutting-edge device not only boasts a revolutionary thickness of just 2.9 mm—comparable to a small coin—but also introduces an array of state-of-the-art features designed to enhance diabetes management.

Revolutionizing Diabetes Care

The GS3 has quickly gained attention for its ultra-compact design and 3-second activation time, making it a standout product at the conference. Weighing merely 1.5 grams, it is so light that users may barely notice it when worn. The device supports three different connection methods, ensuring compatibility with a wide variety of smartphones, which enhances the user experience.

One of the most noteworthy features of the GS3 is its NFC capability; users can easily connect it by simply tapping their smartphone—making glucose monitoring quicker and more efficient. The integration of advanced AI functionalities further aids users in understanding their glucose data, enabling improved self-management of glucose levels.

Additionally, the GS3 can connect directly to smartwatches and a dedicated receiver. This is particularly beneficial for a larger demographic, including children and elderly users, by catering to their specific monitoring needs. Continuous algorithm improvements heighten both the stability and accuracy of glucose monitoring, providing users with an even more reliable tool for diabetes management.

New Insights from the Symposium

SIBIONICS not only launched the GS3 at the ATTD 2025 conference but also hosted the SIBIONICS Symposium, where experts presented research on clinical applications of Continuous Glucose Monitoring (CGM). Attendees learned about the differentiation of Ambulatory Glucose Profile (AGP) patterns across various patient groups, providing significant evidence to advance precision diabetes treatments.

Furthermore, a detailed study on CKM was introduced by clinical experts, focusing on its potential in managing Type 1 diabetes. Preliminary results were shared for the first time at this conference, emphasizing the ongoing exploration of CGM's clinical potential.

With the introduction of the GS3, SIBIONICS reaffirms its commitment to innovation in CGM technology, striving to provide an easier, more precise, and intelligent glucose monitoring system for diabetes patients worldwide.

About SIBIONICS

Founded in 2015, SIBIONICS has emerged as a leading medical technology company with offices in Shenzhen, China, and Irvine, California. The company's expertise lies in the research, development, and innovation of medical devices. Boasting a workforce of over 500 employees, including more than 25% scientists from top universities in China and the USA, SIBIONICS is dedicated to advancing health technology.

The company’s mission is to transform patient lives by providing deeper insights into their health through cutting-edge continuous biosensors, intelligent algorithms, and user-friendly software solutions. By launching the GS3, SIBIONICS aims to empower individuals with diabetes to manage their conditions more effectively and improve their overall quality of life.